Besifovir

Besifovir (INN) is an investigational medication to treat hepatitis B virus (HBV) infection. It is a novel and potent acyclic nucleotide phosphonate with a similar chemical structure to adefovir and tenofovir.[2]

Besifovir

Clinical data
Routes of administration	Oral
ATC code	[1]
Identifiers
IUPAC name [({1-[(2-Amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]phosphonic acid
CAS Number	441785-25-7^Y
PubChem CID	5270766
ChemSpider	4435660^N
UNII	4PLG22CQUU
Chemical and physical data
Formula	C10H14N5O4P
Molar mass	299.227 g·mol^−1
3D model (JSmol)	Interactive image
SMILES NC1=NC=C2N=CN(CC3(OCP(O)(O)=O)CC3)C2=N1
InChI InChI=InChI=1S/C10H14N5O4P/c11-9-12-3-7-8(14-9)15(5-13-7)4-10(1-2-10)19-6-20(16,17)18/h3,5H,1-2,4,6H2,(H2,11,12,14)(H2,16,17,18)^N Key:KDNSSKPZBDNJDF-UHFFFAOYSA-N^N
^NY (what is this?)

References

1. WHO International Working Group for Drug Statistics Methodology (August 27, 2008). "ATC/DDD Classification (FINAL): New ATC 5th level codes". WHO Collaborating Centre for Drug Statistics Methodology. Archived from the original on 2008-05-06. Retrieved 2008-09-05.
2. Lin CL, Yang HC, Kao JH (4 January 2016). "Hepatitis B virus: new therapeutic perspectives". Liver Int. 36 (Supplement S1): 85–92. doi:10.1111/liv.13003. PMID 26725903.